The Latest Cardiac and Vascular News
LAKE FOREST, Calif.–(BUSINESS WIRE)–SinglePass, Inc., developer of the SinglePass biopsy closure device, today announced the publication of a multicenter (Hoag Health System, Newport Beach and Irvine, California) retrospective clinical data study in the Journal of Vascular and Interventional Radiology (JVIR). Across 120 consecutive patients followed for 30 days, the SinglePass device achieved a 100% technical success rate with zero clinically significant bleeding events.1 Percutaneous biopsy
Philips eV14-2v transducer
Philips eV14-2v transvaginal transducer, designed to support a broad range of gynecology and early obstetrics exams.
Clinician holding Philips eV14-2v transducer
A clinician holds the Philips eV14-2v transvaginal transducer.
Patient consultation with Philips Alturion ultrasound
A clinician consults with a patient alongside the Philips Alturion ultrasound system and eV14-2v transducer during a women’s health appointment.
September 3, 2026 FDA 510(k) cleared and CE marked, the eV14-2v combines exceptional image quality and broad clinical capabilities in one lightweight transducer, helping streamline exams, support diagnostic confidence, and improve the patient experience Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced the eV14-2v transvaginal transducer, expanding its obstetrics and gynecology ultrasound portfolio. FDA 510(k) cleared and CE marked, the eV14-2v is designed to support a broad range of gynecology and early obstetrics exams by combining image quality and broad clinical capabilities in a single lightweight transducer. The new transducer will be showcased at the 36th International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) World Congress. Across obstetrics and gynecology, clinicians care for women with diverse clinical needs, from routine gynecologic exams to early pregnancy assessments and more complex cases. Achieving the desired balance of penetration and image resolution may require switching between transducers, which can interrupt workflow and extend exam times. The eV14-2v is designed to address these challenges by providing enhanced penetration, improved resolution, and a wider field of view in a lightweight, ergonomic design. The transducer delivers a 41.7% increase in penetration, a 10% increase in 2D resolution, a 15.8% improvement in field of view, and a 22% lighter design, supporting imaging across routine and complex gynecology and early obstetrics exams [1]. “Advancing women’s health is a priority for Philips ultrasound, and we are committed to developing innovations that make women’s healthcare more accessible and more comfortable for patients,” said Ajay Gannerkote, Ultrasound Business Leader at Philips. “At Philips, we’re focused on bringing together high-quality imaging, intelligent workflows and connected capabilities to simplify the ultrasound experience for clinicians and patients. The eV14-2v transducer reflects that approach, giving clinicians greater versatility in a single transducer and helping support high-quality care for women.” Built specifically for gynecology and obstetrics imaging, the eV14-2v leverages PureWave crystal technology, first introduced by Philips, and features a lightweight ergonomic design that supports user comfort during exams. This gives clinicians detailed visualization of anatomy relevant to evaluating infertility and pelvic pain associated with conditions such as endometriosis and fibroids. Philips technology, including 2D and color resolution, supports the detection of fetal abnormalities, with the ability to delineate the cardiac chambers in a fetus as early as 13 weeks when the heart is the size of a single corn kernel [2]. “Reducing transducer changes during exams has a meaningful impact, not just on efficiency, but on the patient experience as well,” said Dr. Michael S. Ruma, MD, MPH, Perinatal Associates of New Mexico. “With the eV14-2v, we’re able to complete more exams with a single transducer while maintaining excellent image quality, which helps streamline our workflow and improve patient comfort.” The eV14-2v transducer can be used with Philips Collaboration Live, supporting real-time remote consultation during ultrasound exams. Clinicians can view live imaging, provide guidance during exams, and consult with care teams without requiring patient travel. This approach can help expand access to specialty care in underserved communities while supporting more efficient care delivery. In addition to the eV14-2v transducer, attendees at ISUOG 2026 will have the opportunity to experience Philips’ latest women’s healthcare ultrasound innovations firsthand, including the newly launched Alturion ultrasound system, EPIQ Elite, Lumify, and Flash with Collaboration Live, and learn more about the company’s ongoing efforts to advance ultrasound solutions for women worldwide. For further information on the eV14-2v transducer, please visit: Philips – eV14-2v Transducer FUS0929 – Philips. [1] Compared to the 3D9-3v transducer[2] Video image on file For further information, please contact: Jayme Maniatis Philips Global External Relations Tel.: 617-894-8368 E-mail: jayme.maniatis@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
Philips eV14-2v transducer
Clinician holding Philips eV14-2v transducer
Patient consultation with Philips Alturion ultrasound
BRENTWOOD, Tenn. & AUSTIN, Texas–(BUSINESS WIRE)–Heartvue.ai, a cardiac imaging AI company founded by cardiologists, and Innolitics, a medical device software and regulatory consultancy, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance (K260811) for Heartvue.Proton, Heartvue’s machine learning–powered software for viewing, post-processing, and quantitative evaluation of cardiovascular magnetic resonance (MR) images. Innolitics guided Heartvue from initia
WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the diagnosis of cardiac amyloidosis b
CHICAGO–(BUSINESS WIRE)–GE HealthCare today announced three additions to its Vivid™ cardiovascular ultrasound portfolio – Vivid™ Explorer, Vivid™ Advanced and Vivid™ Focus.
Philips MR
Philips and Imricor’s new iMR lab solution combines 1.5T MRI with MR-compatible systems and tools to support MR-guided cardiac interventions.
August 27, 2026 The solution combines Philips’ high-performance 1.5T MRI platform and advanced interventional workflow capabilities with Imricor’s exclusive portfolio of systems and consumables for MR-guided cardiac interventions. Amsterdam, the Netherlands – August 27, 2026: Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration [1] combines Philips’ 1.5T MRI platform and Imricor’s portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only indirect visualization of soft tissue while exposing patients and clinical teams to ionizing radiation. MRI has already transformed cardiac diagnosis by enabling clinicians to visualize cardiac anatomy and tissue in exceptional detail. Bringing that same level of tissue insight into intervention has the potential to help physicians guide therapy more precisely, assess treatment response during procedures and identify potential therapy gaps before a patient leaves the procedure room – all within a radiation-free work environment of an iMR. “Our ambition is not only to advance what clinicians can see with MRI, but also what they can do with it,” said Ioannis Panagiotelis, PhD, Business Leader, Magnetic Resonance at Philips. “Philips has a long history of helping clinicians perform image-guided procedures with confidence, and we believe MRI can play an even greater role in providing care. With this new iMR lab solution, enabled through our collaboration with Imricor, we’re expanding the role of cardiac MRI from diagnosis into the treatment environment.” Panagiotelis added, “Cardiac electrophysiology is just the beginning. This iMR lab solution represents an important step in Philips’ strategy to advance MRI across the care continuum, creating a platform that can expand into additional clinical areas while helping clinicians deliver the best possible care for their patients.” iMR built on Philips’ leading cardiac 1.5T MRI platform The iMR lab solution combines Philips’ high-performance 1.5T MRI platform with Imricor’s portfolio of MR-compatible systems and consumables to create a complete, connected environment for MR-guided cardiac intervention – marking the next milestone in the companies’ long-standing collaboration to bring MR-guided cardiac intervention into routine clinical practice. The first commercially available configuration includes Philips’ Cardiac MR Suite, featuring SmartHeart AI-powered cardiac planning and advanced cardiac imaging applications alongside Imricor’s NorthStar® iMR mapping and guidance system, Advantage-MR® EP Recorder/Stimulator and Vision-MR® family of electrophysiology catheters [2]. Together, these technologies enable physicians to visualize cardiac anatomy and arrhythmia substrate, actively track catheters, perform electroanatomical mapping, assess lesion formation and evaluate treatment response throughout procedures within Philips’ 1.5T MR environment. For hospitals, the iMR lab solution provides a turnkey platform for MR-guided cardiac intervention, bringing together advanced imaging, intelligent workflows and MR-compatible interventional technologies. The solution is built on Philips’ BlueSeal helium-free MRI technology[3], reducing siting complexity and enabling installation closer to cardiology departments, helping support adoption today while establishing a scalable foundation for future iMR-guided procedures. “With interventional MR, the idea is not to move procedures into diagnostic MRI suites, but rather to bring MR imaging into the procedure room, a room we call an iMR lab,” said Steve Wedan, Founder and CEO of Imricor. “Our collaboration with Philips has always been driven by this shared vision, and with our combined iMR lab solution, that vision becomes a reality today. Pairing Philips’ world-class 1.5T MR platform with Imricor’s exclusive portfolio of advanced iMR systems and interventional tools creates the world’s first state-of-the-art high-performance iMR lab solution. We believe the future is about advanced image guidance for therapies and interventions, and the future is here now.” The iMR lab solution will be showcased in Munich at ESC Congress 2026 and is commercially available immediately in CE-marked markets and, in some configurations, the U.S. Further Imricor configurations are expected to become available in the U.S. and additional markets, subject to regulatory clearances. [1] Philips issued a Third-Party Product Compatibility Declaration for Imricor’s interventional MRI (iMR) equipment and consumables. [2] NorthStar and the Vision-MR Diagnostic Catheter are commercially available in the U.S. Other Imricor products are not yet cleared/approved for sale in the U.S. [3] Helium-free operations. 7 liters of helium is permanently enclosed in the cryogenic circuit. For further information, please contact: Name Jayme ManiatisPhilips Global External RelationsTel.: +16178948368E-mail: jayme.maniatis@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. About Imricor Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance (MR) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MR’s superior imaging capabilities.
Attachment
Philips MR
Commercial initiative aims to make VMS+ easier for hospitals to evaluate and adoptTORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) — Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV: VPT; OTC: VPTDF), a leader in AI-assisted cardiac imaging, today announced the next phase of its commercial strategy for VMS+™ 4.0, its FDA-cleared platform that turns standard heart-ultrasound images into three-dimensional cardiac measurements. The Company is expanding subscription-based access, hospital demonstrations, and customer-engagement programs to help more hospitals evaluate and adopt VMS+. The objective is straightforward: expand access to advanced heart imaging using ultrasound systems hospitals already have. Hospitals, cardiac programs, distributors and strategic partners interested in evaluating VMS+, requesting a demonstration, or learning more about subscription access are invited to visit www.ventripoint.com or contact the Company directly. VMS+ uses artificial intelligence and Ventripoint’s proprietary Knowledge Based Reconstruction technology to create 3D models and quantitative measurements of all four chambers of the heart. The system is designed to provide MRI-comparable volumetric cardiac measurements while fitting into the more widely available heart-ultrasound workflow. Addressing a Common Hospital Barrier One of the primary barriers to adoption of new medical technology is often not clinical interest, but the capital-budget and procurement process. To help address that, Ventripoint is expanding its Device-as-a-Service (“DaaS”) model. This gives qualified hospitals and cardiac programs the option to access VMS+ through an annual subscription instead of relying solely on a traditional upfront capital purchase. The Company is targeting an approximately 80/20 weighting toward subscription-based access, while continuing to support capital-purchase options for institutions that prefer them. Subscription arrangements are designed to include: installationonboardingclinical trainingsoftware updatestechnical support “Hospitals can recognize the value of a technology long before it fits neatly into a capital budget,” said Hugh MacNaught, President and Chief Executive Officer of Ventripoint Diagnostics. “Our subscription model is designed to reduce that friction. It gives qualified hospitals another path to evaluate and implement VMS+ without relying solely on a large upfront equipment purchase.” What VMS+ Does Heart ultrasound is among the most widely used tools in cardiac care. But measuring complex heart anatomy—especially the right ventricle—can still be difficult using conventional two-dimensional imaging alone. VMS+ is designed to enhance that process by adding AI-assisted, three-dimensional analysis to standard heart-ultrasound exams. VMS+ 4.0: creates 3D models and measurements of all four heart chambersprovides ventricular volumes and ejection-fraction measurementsworks alongside supported ultrasound systems already used in hospitalsis designed to provide MRI-comparable volumetric measurementsincludes AI-assisted point placementdoes not require hospitals to replace their existing ultrasound systems VMS+ 4.0 received U.S. FDA 510(k) clearance in 2025. The platform also holds regulatory approvals in Canada, the European Union and the United Kingdom and received a 2026 Gold Edison Award in Precision Health Technologies. Momentum Across Real-World Care Settings Ventripoint’s commercial expansion comes as VMS+ continues gaining traction across a range of healthcare settings. In July, VMS+ was selected for the AIRES – Artificial Intelligence Reconstruction of Echocardiography Study, led by The Royal Wolverhampton NHS Trust in the United Kingdom. The NHS describes AIRES as the world’s first study evaluating AI-enabled heart ultrasound specifically in oncology patients. The study focuses on patients receiving chemotherapy for breast cancer and is expected to involve more than 500 echocardiography scans. Researchers will study whether AI can improve the accuracy, speed and efficiency of cardiac monitoring. AIRES is ongoing, and no clinical outcome should be inferred at this stage. Separately, Ventripoint recently signed an MOU with UniDoc Health Corp. to evaluate the potential integration of VMS+ into connected-care infrastructure for remote cardiac assessment and cardiovascular screening. The proposed model could support imaging access in remote, rural, Indigenous and other underserved communities, subject to further agreements. “What is exciting is not just the technology itself, but where it can be used,” MacNaught added. “We are seeing interest in settings that range from specialist cardiac care to oncology research to remote-health models. That suggests the need for better, more accessible cardiac information is much broader than one single use case.” Designed for Workflow and Adoption Commercial adoption is driven by usability, not solely technical capability. In a formal human-factors and usability study of VMS+ 3.0 involving 13 cardiac sonographers and healthcare professionals, Ventripoint reported: 98% task completionno critical errorsan average workflow completed within 15 minutes Participants completed acquisition, analysis, 3D visualization and reporting tasks in a simulated hospital environment. VMS+ 4.0 later added AI-assisted point placement intended to further support workflow efficiency. “Clinicians need tools that are practical, not just powerful,” said MacNaught. “The usability data showed that trained professionals were able to complete the workflow quickly and successfully. That matters because adoption depends on how a technology fits into real clinical practice.” From Validation to Broader Adoption Ventripoint is now focused on turning years of development, research, and regulatory work into broader commercial adoption. Current priorities include: expanding hospital evaluations and product demonstrationsincreasing subscription-based access in approved marketssupporting onboarding, training and implementationexpanding distributor, clinical and strategic relationshipsincreasing awareness among healthcare systems, cardiologists and patient organizations Current and previous generations of Ventripoint technology are used by hospitals in North America and Europe. The Company has also submitted VMS+ 4.0 for regulatory approval in China through strategic partner Lishman Global, which qualified for the NMPA’s expedited “green channel” review pathway. Frequently Asked Questions What is VMS+?VMS+ is Ventripoint’s AI-assisted cardiac imaging platform. It uses standard heart-ultrasound images to create 3D models and quantitative measurements of all four chambers of the heart. Does VMS+ replace cardiac MRI?No. Cardiac MRI remains an important clinical reference standard. VMS+ is designed to provide MRI-comparable volumetric cardiac measurements through the more widely available heart-ultrasound workflow. What problem does the subscription model solve?Many hospitals face long capital-budget and procurement cycles when buying new technology. Ventripoint’s subscription model gives qualified institutions another way to access VMS+. What is included in subscription access?Subscription access is designed to include installation, onboarding, clinical training, software updates and technical support. Is Ventripoint using AI to detect breast cancer?No. In the AIRES study, VMS+ is being evaluated to monitor heart function in patients receiving breast cancer treatment. It does not detect or diagnose breast cancer. How can a hospital evaluate VMS+?Hospitals and cardiac programs can contact Ventripoint to request a demonstration, discuss an evaluation or learn more about subscription-based access. About Ventripoint Diagnostics Ltd. Ventripoint Diagnostics Ltd. (TSXV: VPT; OTC: VPTDF) is a leader in the application of artificial intelligence to echocardiography. Ventripoint’s VMS+™ platform is powered by its proprietary Knowledge Based Reconstruction technology, developed over more than a decade and designed to provide accurate volumetric cardiac measurements equivalent to MRI for all four chambers of the heart. VMS+ is compatible with leading ultrasound systems from major vendors and designed for deployment across hospital, community, and remote-care settings. The platform delivers advanced cardiac imaging and longitudinal ventricular function analysis without requiring additional imaging hardware, supporting broader access to specialist-quality cardiac assessment. For more information, visit www.ventripoint.com. Contact Ventripoint Diagnostics Ltd.Hugh MacNaughthmacnaught@ventripoint.com(604) 671-4201 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Forward-Looking Statements This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws
On-premise medical imaging AI framework uses Intel Core Ultra processors and Intel’s OpenVINO toolkit to accelerate edge inference within healthcare environments PETACH TIKVA, Israel – August 10 – Nanox AI Ltd., a subsidiary of Nano-X Imaging Ltd. (NASDAQ: NNOX), today announced the optimization of its medical imaging AI application framework for Intel CoreUltra processors using Intel’s OpenVINO toolkit. The framework is designed to support AI applications running on an on-premise edge device within healthcare facilities, enabling organizations to evaluate and deploy CT imaging AI applications while keeping imaging data within their own infrastructure. Nanox.AI solutions analyze routine medical CT scans to help identify patients with findings correlated with chronic conditions in areas including cardiac, liver and bone health. By leveraging existing CT imaging workflows, Nanox.AI aims to help healthcare organizations derive additional clinical value from scans that have already been performed and support preventive care management. The optimized AI application framework ran inference successfully and efficiently on Intel Core Ultra-class hardware using OpenVINO, demonstrating its suitability for on-premise AI processing in medical imaging environments. Intel Core Ultra processors provide a heterogeneous AI architecture with CPU, GPU and NPU compute resources, while OpenVINO helps developers optimize and deploy AI workloads across Intel hardware. For healthcare organizations, this combination can support local inference at the edge, help reduce dependence on cloud connectivity, and enable deployment models aligned with hospital infrastructure requirements. “Nanox.AI is focused on helping healthcare organizations deploy advanced medical imaging AI applications efficiently within their existing infrastructure,” said Sharon Saban, General Manager of Nanox.AI. “Our work with Intel demonstrates how optimized edge inference can help bring AI-enabled imaging insights closer to the point of care.” “Healthcare organizations need practical ways to bring AI closer to clinical workflows while supporting performance, responsiveness and local data control,” said Alex Flores, General Manager, Health and Life Science, Edge Computing GroupGoup, Intel. “Nanox.AI’s optimization work with Intel Core Ultra processors and Intel’s OpenVINO toolkit shows how edge AI can help medical imaging applications run efficiently on-premise, giving providers a scalable path to evaluate and deploy AI-enabled insights within their existing infrastructure.” Nanox.AI’s technology has also been featured in Intel’s partner resources as an example of a solution built with Intel technology in Intel’s published partner brief. For more information about Nanox.AI and its suite of solutions, visit www.nanox.vision/ai. ©Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries. 1 See intel.com/processor claims: Intel® Core™ Ultra Processors (Series 3). Performance varies by use, configuration, and other factors. Results may vary. Intel does not control or audit third-party data. You should consult other sources to evaluate accuracy. About Nanox Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform. Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes. The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provides access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery. By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit https://www.nanox.vision. About Nanox.AI Nanox.AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox.AI solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI, Nanox.AI helps clinicians extract valuable and actionable clinical insights from medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. For more information, please visit www.nanox.vision/ai. Forward-Looking Statements This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, statements regarding: the Company’s expected commercialization efforts, business strategy and long-term growth opportunities; the expected timing, pace, extent and success of deployments, installations, activations and utilization of Nanox.ARC systems, including under the Nanox Imaging Network; the anticipated benefits, timing and extent of activity under existing commercial, distribution and strategic agreements, including contemplated deployments of hundreds of systems over the coming years; the potential outcome, scope and timing of the evaluation of strategic alternatives relating to the Company’s South Korea operations, including an expanded restructuring, a potential sale, wind-down or closure of all or part of such operations; the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of Nanox’s liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; (iv) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (v) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (vi) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vii) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (viii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (ix) Nanox’s ability to conduct business globally; (x) changes in global, political, economic, business, competitive, market and regulatory forces; (xi) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; and (xii) risks related to litigation which may result in significant liability and damage to the Company’s reputation. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations. Contacts Media Contact:Ben ShannonICR HealthcareNanoxPR@icrinc.com Investor Contact:Mike CavanaughICR Healthcaremike.cavanaugh@icrhealthcare.com
GUILFORD, Conn.–(BUSINESS WIRE)–Multiple peer-reviewed publications in Journal of Neurosurgery and Stroke strengthen evidence for portable MRI in stroke and neurosurgical settings.
CorVascular Launches ASUS Handheld Ultrasound Portfolio for Vascular Specialists at SVU 2026
